logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Why Seattle Genetics Gained $13.29; Currently Trading at $100.69; Meeting the Prohost 2019 Target

Seattle Genetics Announced Positive Results for HER2CLIMB Trial Seattle Genetics ( SGEN ) announced positive topline results from the HER2CLIMB trial evaluating tucatinib in HER2- positive breast cancer .  The trial compared tucatinib in combination with trastuzumab and capecitabine to trastuzumab...

Read More

October 21, 2019

0

Spark Therapeutics: An encouraging attempt to dethrone enzyme replacement as the standard of care treatment for Pompe Disease.

On Saturday, October 6, 2018, Spark Therapeutics (ONCE) presented positive data from a preclinical trial with SPK-3006 for the treatment of Pompe disease in an oral presentation at the 23 rd  International Congress of the World Muscle Society in Argentina. SPK-3006 is an investigational liver-directed adeno-associated...

Read More

October 9, 2018

0

The Small Stock That Refused to Kneel in Today's Market

Compugen Soaring in an Extremely Down Market The stocks' prices tumbled today except for very few and one of them is Compugen ( CGEN ) . This firm announced good news; we wish it has chosen a better day for...

Read More

March 9, 2020

0

The Market Rebounding That Left Important Biotechnology Firms Behind

COVID-19, The Market Rebounding and the Biotech Firms That Did and Didn't Rally The Market Rebounding included: Amgen ( AMGN ) , Biogen ( BIIB ) and Incyte ( INCY ); t he only biotechnology firms to rebound in early...

Read More

March 13, 2020

0

After being approved for Eczema, Regeneron's and Sanofi's product, Dupixent, succeeded in treating chronic rhinosinusitis, nasal polyps and asthma.

In two pivotal Phase 3 placebo-controlled trials Regeneron Pharmaceuticals’ (REGN) and Sanofi’s (SNY) drug,  Dupixent® (dupilumab), demonstrated a significant reduction in nasal polyp size, nasal congestion’s severity and the need for systemic corticosteroids and/or surgery. Both trials were evaluating Dupixent® (dupilumab) in...

Read More

October 16, 2018

0

IVERIC bio Stock Doubled and Continues to Outperform

IVERIC bio Stock Outperforms IVERIC bio ( ISEE ) has good news its stock is responding to. A randomized, controlled Phase 2b clinical trial data seem to confirm that the IVERIC bio product Zimura® (avacincaptad pegol), a complement factor C5...

Read More

November 1, 2019

0

Why VTV Therapeutics' stock added over 48% to its price before trading hours today

VTV Therapeutics’ (VTVT) stock price added over 48% before trading hours today. The news that some believe is behind investors’ enthusiasm is the firm’s announcement that it will deliver two presentations at the 11 th clinical trials on Alzheimer’s Disease...

Read More

October 17, 2018

0

Why Portola's stock decline

Why Portola’s Stock Decline Everybody interested in Portola (PTLA) knows by now that this firm has managed to put two FDA-approved products on the market. They are: Bevyxxa ®  (betrixaban):  The first and only once-daily oral Factor Xa inhibitor, for the prevention...

Read More

October 17, 2018

0

Karyopharm Therapeutics: Is a Star Born?

Karyopharm Therapeutics Third Quarter Financial Results Generated Revenues For the first time since its establishment Karyopharm Therapeutics ( KPTI ) financial results report revenues from a strong launch of its first approved product. Indeed, the firm’s third-quarter 2019 financial results...

Read More

November 6, 2019

0

Good News for Exelixis and for Japanese Renal Cell Carcinoma Patients

Exelixis, Takeda and Japanese RCC Patients Today we learned from Exelixis ( EXEL ) that Takeda Pharmaceutical Company Limited , which is responsible for the clinical development and commercialization of Exelixis' oncology drug   CABOMETYX® (cabozantinib) in Japan, informed that...

Read More

March 25, 2020

0

  • Previous
  • 1
  • 2
  • ...
  • 84
  • 85
  • 86
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy